Trophos Blueprints Path To Exit With Actelion Option Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Trophos' deal with Actelion provides validation for the biotech's approach to rare disease R&D and lines up a solid exit for Trophos' venture backers - if Phase III data lives up to expectations.